{
    "nctId": "NCT01144572",
    "briefTitle": "Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment",
    "officialTitle": "A Prospective, Multicenter, Non-interventional Study to Evaluate Quality of Life in Chinese Postmenopausal HR(+) EBC Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 494,
    "primaryOutcomeMeasure": "The change of the trial outcome index (TOI) of the FACT-B questionnaire from baseline to 24 months.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women \u2264 70 years old, with histologically proven HR (+) early breast cancer.\n* Undergoing upfront AIs adjuvant treatment within 7 days.\n\nExclusion Criteria:\n\n* Patients who disagree to participate this study\n* Patients who, for whatever reason (eg, confusion, infirmity), are unlikely to comply with trial requirements.\n* The AIs have not been approved by SFDA for the indication of upfront adjuvant endocrine therapy in early breast cancer.",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}